Rothschild Redburn downgrades Moderna to Sell with $81 PT

Rothschild Redburn downgraded Moderna (MRNA) to Sell with an $81 price target. The analyst called the Phase 3 melanoma vaccine result 'a great result' but said the stock now appears to price in broad use across multiple tumor types where there is little or no supporting data.